ArticleSurgical case reports2026
Pathological Complete Response after Conversion Surgery for Distal Cholangiocarcinoma with High Tumor Mutational Burden and Para-Aortic Lymph Node Metastasis: A Case Report.
Article in Surgical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPathological complete response (pCR) following conversion resection after chemotherapy for initially unresectable distal cholangiocarcinoma (DCC) is rare. The efficacy of the immune checkpoint inhibitors (ICIs) pembrolizumab and durvalumab for treating unresectable biliary tract cancer (BTC) has been reported in randomized trials, and they are used as first-line therapies, regardless of specific genetic mutations. High tumor mutation burden (TMB-High) has gained attention as a biomarker for predicting treatment response to ICI; however, it has been reported to be rare in BTC. CASE PRESENTATION: A 78-year-old man was referred to our hospital after mild liver dysfunction was detected during a routine medical checkup. Contrast-enhanced CT revealed wall thickening with contrast enhancement of the distal bile duct. Endoscopic ultrasonography revealed an irregular hypoechoic mass in the distal bile duct. Endoscopic retrograde cholangiopancreatography confirmed a distal bile duct stricture, and biopsy of the stricture site confirmed adenocarcinoma. Further evaluation revealed DCC with para-aortic lymph node (PALN) metastasis. The tumor was initially considered unresectable. Comprehensive cancer genomic profiling using tissue samples revealed TMB-High. The patient underwent 8 cycles of systemic chemotherapy consisting of gemcitabine, cisplatin, and durvalumab, followed by durvalumab monotherapy. After more than 1 year of chemotherapy, improvement in the bile duct stricture was confirmed, and complete disappearance of fluorodeoxyglucose uptake in the primary lesion and PALNs was observed. Based on these findings, conversion surgery was considered feasible, and subtotal stomach-preserving pancreaticoduodenectomy was performed. Histopathological examination revealed no residual tumor in the distal bile duct or PALNs. The therapeutic effect was grade 4, indicating pCR. The patient remains alive without recurrence 6 months after surgery.
conclusionsWe encountered a case of TMB-High DCC in which conversion resection became feasible after systemic chemotherapy including the ICI durvalumab, resulting in pCR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.